The Food and Drug Administration on Tuesday approved a new dose of Merck's HIV drug Isentress.
Patients may now take a 1,200 milligram once-daily dose of Isentress in combination with other antiretroviral treatments. Merck already offers the drug in a 400 milligram twice-daily formulation.
Merck expects the new version of the drug to hit pharmacy shelves within a month.
More articles on supply chain:
Amgen sues FDA over drug exclusivity rights: 5 things to know
Appellate court: Fairvew Health's medical device telemarketing does not violate robocall rules
Drug execs anticipate Trump's drug pricing plans: 4 things to know